标题：VEGF、MMP-2和MMP-9检测在子宫内膜异位症诊断中的应用价值

      作者：朱锋，彭启松，居蓉
    (南京市江宁医院检验科，江苏 南京 211100)

      卷次： 2016年27卷6期

      【摘要】 目的 检测子宫内膜异位症(EMs)患者血清及腹腔液中血管内皮生长因子(VEGF)、基质金属蛋白
酶-2 (MMP-2)和基质金属蛋白酶-9 (MMP-9)的浓度，并探讨其与EMs的诊断及分期的意义。方法 采用酶联免
疫吸附法(ELISA)定量测定 2012年 1月至 2014年 12月于我院妇科住院的 64例EMs患者血清和腹腔液中VEGF、
MMP-2和MMP-9浓度，并与 30例子宫肌瘤患者(非EMs组)进行比较分析。结果 EMs组患者血清中VEGF、
MMP-2和MMP-9浓度分别为(235.7±61.2) ng/L、(196.3±51.8) μg/L和(231.6±44.0) μg/L，腹腔液中VEGF、MMP-2
和MMP-9浓度分别为 (856.2±260.5) ng/L、(45.1±13.6)μg/L和 (53.4±19.0) μg/L。EMs组患者血清及腹腔液中
VEGF、MMP-2和MMP-9浓度显著高于非EMs组，Ⅲ~Ⅳ期浓度显著高于Ⅰ~Ⅱ期和非EMs组(P<0.01)；Ⅰ~Ⅱ期中
VEGF浓度显著高于非EMs组(P<0.01)。结论 在EMs患者血清及腹腔液中高浓度的VEGF、MMP-2和MMP-9
与EMs的发生和发展相关，检测VEGF、MMP-2和MMP-9浓度有助于EMs的诊断与分期评估。

      【关键词】 子宫内膜异位症；血管内皮生长因子；基质金属蛋白酶-2；基质金属蛋白酶-9

      【中图分类号】 R711.71 【文献标识码】 A 【文章编号】 1003—6350（2016）06—0880—03


Application value of testing VEGF, MMP-2 and MMP-9 in the diagnosis of endometriosis.
ZHU Feng, PENG
Qi-song, JU Rong. Department of Clinical Laboratory, the Jiangning Hospital of Nanjing, Nanjing 211100, Jiangsu, CHINA

【Abstract】 Objective To detect the levels of vascular endothelial growth factor (VEGF), matrix metalloprotein-
ase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in sera and peritoneal fluid, and to study their relationship with
the diagnosis and staging of endometriosis (EMs). Methods The concentrations of VEGF, MMP-2 and MMP-9 were de-
termined by enzyme-linked immunosorbent assay (ELISA) in sera and peritoneal fluid from 64 patients with EMs (EMs
group) from Jan. 2012 to Dec. 2014 in the Department of Gynaecology in our hospital. The results were compared with
those of 30 patients with hysteromyoma (non-EMs group). Results The concentrations of VEGF, MMP-2, MMP-9 were
(235.7±61.2) ng/L, (196.3±51.8) μg/L, (231.6±44.0) μg/L in sera in EMs group and (856.2±260.5) ng/L, (45.1±13.6) μg/L
and (53.4±19.0) μg/L in peritoneal fluid in EMs group. The concentrations of VEGF, MMP-2 and MMP-9 in sera and peri-
toneal fluid in EMs group were significantly higher than those of the non-EMs group, and the concentrations were signifi-
cantly higher in EMs patients ofⅢ~Ⅳ stage than those in EMs patients ofⅠ~Ⅱ stage and non-EMs group (P<0.01), and
also in EMs patients ofⅠ~Ⅱ stage than those in non-EMs group (P<0.01). Conclusion The higher expression of VEGF,
MMP-2 and MMP-9 in serum and peritoneal fluid in EMs patients suggested that they were associated with the occur-
rence and development of EMs. Detecting the concentrations can be helpful for the diagnosis and stage evaluation.

      【Key words】 Endometriosis (EMs); Vascular endothelial growth factor (VEGF); Matrix metalloproteinase-2
(MMP-2); Matrix metalloproteinase-9 (MMP-9)
·论 著·
6350.2016.06.007